Literatur
- 1
Talamini R et al.
The role of reproductive and menstrual factors in cancer of the breast before and
after menopause.
Eur J Cancer.
1996;
32A
303-310
- 2
Peer P G et al.
Age-dependent growth rate of primary breast cancer.
Cancer.
1993;
71
3547-3551
- 3
Ewertz M et al.
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies
from the Nordic countries.
Int J Cancer.
1990;
46
597-603
- 4
███ .
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological
studies including 58 209 women with breast cancer and 101 986 women without the disease.
Lancet.
2001;
358
1389-1399
- 5
Yarbro J W et al.
American Joint Committee on Cancer prognostic factors consensus conference.
Cancer.
1999;
86
2436-2446
- 6
Dupont W D et al.
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.
Cancer.
1993;
71
1258-1265
- 7
Adami H O, Bergstrom R, Hansen J.
Age at first primary as a determinant of the incidence of bilateral breast cancer.
Cumulative and relative risks in a population-based case-control study.
Cancer.
1985;
55
643-647
- 8
Speroff L.
The meaning of mammographic breast density in users of postmenopausal hormone therapy.
Maturitas.
2002;
41
171-175
- 9
Warner E et al.
The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis
of the published literature to examine the effect of method of classification.
Cancer Detect Prev.
1992;
16
67-72
- 10
Franceschi S et al.
Body size indices and breast cancer risk before and after menopause.
Int J Cancer.
1996;
67
181-186
- 11
Collaborative Group on Hormonal Factors in Breast Cancer .
Breast cancer and hormonal contraceptives: collaborative reanalysis of individual
data on 53 297 women with breast cancer and 100 239 women without breast cancer from
54 epidemiological studies.
Lancet.
1996;
347
1713-1727
- 12
Collaborative Group on Hormonal Factors in Breast Cancer .
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from
51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without
breast cancer.
Lancet.
1997;
350
1047-1059
- 13
Chen C L et al.
Hormone replacement therapy in relation to breast cancer.
J Am Med Assoc.
2002;
287
734-741
- 14
Meindl A.
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1
and BRCA2 mutation profiles and frequencies for the German population.
Int J Cancer.
2002;
97
472-480
- 15
Eeles R A.
Future possibilities in the prevention of breast cancer: intervention strategies in
BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res.
2000;
2
283-290
- 16
Barton M B, Harris R, Fletcher S W.
The rational clinical examination. Does this patient have breast cancer? The screening
clinical breast examination: should it be done? How?.
J Am Med Assoc.
1999;
282
1270-1280
- 17
Semiglazov V F et al.
Results of a prospective randomized investigation (Russia [St. Petersburg] / WHO)
to evaluate the significance of self-examination for the early detection of breast
cancer.
Vopr Onkol.
2003;
49
434-441
- 18
Thomas D B et al.
Randomized trial of breast self-examination in Shanghai: final results.
J Natl Cancer Inst.
2002;
94
1445-1457
- 19
Thurfjell E L, Lindgren J A.
Breast cancer survival rates with mammographic screening: similar favorable survival
rates for women younger and those older than 50 years.
Radiology.
1996;
201
421-426
- 20
Olsen O, Gotzsche P C.
Cochrane review on screening for breast cancer with mammography.
Lancet.
2001;
358
1340-1342
- 21
Tabar L et al.
Beyond randomized controlled trials: organized mammographic screening substantially
reduces breast carcinoma mortality.
Cancer.
2001;
91
1724-1731
- 22
Shapiro S.
Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health
Insurance Plan.
J Natl Cancer Inst Monogr.
1997;
22
27-30
- 23
Andersson I et al.
Mammographic screening and mortality from breast cancer: the Malmo mammographic screening
trial.
Brit Med J.
1988;
297
943-948
- 24
Frisell J et al.
Randomized study of mammography screening – preliminary report on mortality in the
Stockholm trial.
Breast Cancer Res Treat.
1991;
18
49-56
- 25
Bjurstam N et al.
The Gothenburg breast screening trial: first results on mortality, incidence, and
mode of detection for women ages 39–49 years at randomization.
Cancer.
1997;
80
2091-2099
- 26
Miller A B et al.
The Canadian National Breast Screening Study: update on breast cancer mortality.
J Natl Cancer Inst Monogr.
1997;
22
37-41
- 27
Andersson I, Janzon L.
Reduced breast cancer mortality in women under age 50: updated results from the Malmo
Mammographic Screening Program.
J Natl Cancer Inst Monogr.
1997;
22
63-67
- 28
Frisell J, Lidbrink E.
The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40–49 years.
J Natl Cancer Inst Monogr.
1997;
22
49-51
- 29
Tabar L et al.
Efficacy of breast cancer screening by age. New results from the Swedish Two-County
Trial.
Cancer.
1995;
75
2507-2517
- 30
Tabar L et al.
What is the optimum interval between mammographic screening examinations? An analysis
based on the latest results of the Swedish two-county breast cancer screening trial.
Br J Cancer.
1987;
55
547-551
- 31 Schulz K, Albert U et al. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. Zuckerschwerdt,
München 2003
- 32
Jackson V P.
The role of US in breast imaging.
Radiology.
1990;
177
305-311
- 33
Ciatto S et al.
The diagnostic role of breast echography.
Radiol Med (Torino).
1994;
88
221-224
- 34
Madjar H et al.
Preoperative staging of breast cancer by palpation, mammography and high-resolution
ultrasound.
Ultrasound Obstet Gynecol.
1993;
3
185-190
- 35
Madjar H et al.
Value of high resolution sonography in breast cancer screening.
Ultraschall Med.
1994;
15
20-23
- 36
Hille H, Vetter M, Hackeloer B J.
Re-evaluating the role of breast ultrasound in current diagnostics of malignant breast
lesions.
Ultraschall Med.
2004;
25
411-417
- 37
Madjar H et al.
Phantom studies of ultrasound equipment for quality improvement in breast diagnosis.
Ultraschall Med.
1996;
17
85-95
- 38
Heywang-Kobrunner S H et al.
International investigation of breast MRI: results of a multicentre study (11 sites)
concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically
correlated lesions.
Eur Radiol.
2001;
11
531-546
- 39
Kuhl C K et al.
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.
Lancet.
2007;
370
485-492
- 40
Kneeshaw P J, Turnbull L W, Drew P J.
Current applications and future direction of MR mammography.
Br J Cancer.
2003;
88
4-10
- 41
Sardanelli F, Iozzelli A, Fausto A.
MR imaging of the breast: indications, established technique, and new directions.
Eur Radiol.
2003;
13
N28-N36
- 42
Hahn M.
BI-RADS analoge DEGUM Kriterien zur Klassifikation der Ultraschalluntersuchung der
Brust.
Senologie.
2007;
4
21
- 43
Madjar H et al.
BI-RADS-analogue DEGUM criteria for findings in breast ultrasound – consensus of the
DEGUM Committee on Breast Ultrasound.
Ultraschall Med.
2006;
27
374-379
- 44
Azavedo E, Svane G, Auer G.
Stereotactic fine-needle biopsy in 2594 mammographically detected non-palpable lesions.
Lancet.
1989;
1
1033-1036
- 45
Dempsey P J, Rubin E.
The roles of needle biopsy and periodic follow-up in the evaluation and diagnosis
of breast lesions.
Semin Roentgenol.
1993;
28
252-258
- 46
Dent D M et al.
Stereotaxic localisation and aspiration cytology of impalpable breast lesions.
Clin Radiol.
1989;
40
380-382
- 47
Dowlatshahi K et al.
Nonpalpable breast lesions: findings of stereotaxic needle-core biopsy and fine-needle
aspiration cytology.
Radiology.
1991;
181
745-750
- 48
Kopans D B.
Review of stereotaxic large-core needle biopsy and surgical biopsy results in nonpalpable
breast lesions.
Radiology.
1993;
189
665-666
- 49
Meyer J E et al.
Occult breast calcifications sampled with large-core biopsy: confirmation with radiography
of the specimen.
Radiology.
1993;
188
581-582
- 50
Parker S H et al.
Percutaneous large-core breast biopsy: a multi-institutional study.
Radiology.
1994;
193
359-364
- 51
Poilpot S et al.
Stereotactic excisional nonpalpable breast lesions using the advanced breast biopsy
instrumentation.
J Gynecol Obstet Biol Reprod.
2000;
29
142-147
- 52
Fishman J E et al.
US-guided core-needle biopsy of the breast: how many specimens are necessary?.
Radiology.
2003;
226
779-782
- 53 Hahn M, Krainick-Strobel U, Wallwiener D. Die ultraschallgesteuerte Vakuumbiospie
– ein Lehrvideo. Universitäts-Frauenklinik, Tübingen 2006
- 54
Hahn M et al.
Is a handheld mammotome suitable for the complete removal of benign breast lesions?.
Geburtsh Frauenheilk.
2004;
64
719-722
- 55
Hahn M et al.
Evaluation von Komplikationen unter stereotaktischer Vakuumbiopsie der Brust.
Geburtsh Frauenheilk.
2000;
60
115
- 56
Heywang-Kobrunner S H et al.
Interdisciplinary consensus on the use and technique of vacuum-assisted stereotactic
breast biopsy.
Eur J Radiol.
2003;
47
232-236
- 57
Krainick-Strobel U.
Die Ultraschall (US)-geführte Vakuumbiopsie (VB) der Brust: Entwicklung eines Simulationsmodells,
Auswertung von Patientinnenuntersuchungen, Erarbeitung des Indikationsspektrums und
Konsensusempfehlung zur Anwendung der Methode.
Geburtsh Frauenheilk.
2005;
65
526-529
- 58
Krainick-Strobel U et al.
Consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic
guidance.
Gynecological Surgery.
2006;
3
309-314
- 59
Scheler P et al.
Handheld ultrasound-guided vacuum biopsy of mammary lesions – first experiences.
Zentralbl Gynakol.
2000;
122
472-475
- 60
Fischer U.
MR-gesteuerte Interventionen, Empfehlungen der AG Mammmadiagnostik der Deutschen Röntgengesellschaft,
Konsensus 02 / 2007.
Fortschr Röntgenstr.
2007;
179
429-430
- 61
Liberman L, Sama M P.
Cost-effectiveness of stereotactic 11-gauge directional vacuum-assisted breast biopsy.
Am J Roentgenol.
2000;
175
53-58
- 62
Hahn M et al.
Fehlerquellen bei minimalinvasiven Interventionen der Brust … und wie man sie umgehen
kann!.
Geburtsh Frauenheilk.
2007;
67
779-781
Dr. med. I. Gruber
Universitäts-Frauenklinik Tübingen
Calwer Str. 7
72076 Tübingen
eMail: Ines.Gruber@med.uni-tuebingen.de
